Webinar – Parp-Inhibitors and Prostate Cancer…Gotta Have a Mutation???

Virtual

Parp-Inhibitors have long been on AnCan's radar since our dear departed Boardie, Dr. Bill Burhans, found himself with olaparib in his lab in 2015 and convinced his tumor board to prescribe it along with abiraterone for his BRCA2 mutation.

Question is ...

What's a PARP-Inhibitor, and what does it do?

Who benefits from a PARP?

Do PARP-I's work for everybody?

How can a PARP-I be used for prostate cancer?

Event Series Under-60 Advanced Prostate Cancer

Under-60 Advanced Prostate Cancer

GoTo Meeting - Barniskis Room

Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.